Xalkori (Crizotinib) Patent Expiration, LOE Window & CMS Spending
Xalkori (Crizotinib) by Pfizer: FDA Orange Book core substance LOE 2029-11-06, 0 AB generics, $71.4M 2024 CMS Part D & Medicaid spend, and 6 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Pfizer |
| FDA Application & Pathway | N202570 (NDA) |
| Exclusivity / Cliff Horizon | Near-Term Cliff (2028-2030) |
| Core Active-Ingredient LOE Date | 2029-11-06 |
| Last Listed Patent or Exclusivity Date | 2029-11-06 |
| Orange Book Patents (*PED Extensions) | 3 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $71.4M |
| 2024 Medicare Part D Spend | $58.9M |
| 2024 Medicaid Spend | $12.5M |
| Reported Wholesale Price Change (CA SB 17) | 6 WAC filings (max 21.2% 2-yr change) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Pfizer across sibling Meru public-data platforms.